Trial Profile
A Phase 2, Double - Blind, Placebo - Controlled, Randomized Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2014
Price :
$35
*
At a glance
- Drugs Recombinant alpha fetoprotein (Primary)
- Indications Uveitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 28 May 2014 New trial record